allisartan-isoproxil and Cerebrovascular-Disorders

allisartan-isoproxil has been researched along with Cerebrovascular-Disorders* in 1 studies

Other Studies

1 other study(ies) available for allisartan-isoproxil and Cerebrovascular-Disorders

ArticleYear
Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage.
    Acta pharmacologica Sinica, 2021, Volume: 42, Issue:6

    Stroke is a common cause of death and disability. Allisartan isoproxil (ALL) is a new angiotensin II receptor blocker and a new antihypertensive drug discovered and developed in China. In the present study we investigated the therapeutic effects of ALL in stroke-prone renovascular hypertensive rats (RHR-SP) and the underlying mechanisms. The model rats were generated via two-kidney two-clip (2K2C) surgery, which led to 100% of hypertension, 100% of cerebrovascular damage as well as 100% of mortality 1 year after the surgery. Administration of ALL (30 mg · kg

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Aortic Diseases; Biphenyl Compounds; Blood Pressure; Brain; Cerebrovascular Disorders; Heart; Hypertension; Imidazoles; Kaplan-Meier Estimate; Kidney; Myocardium; Oxidative Stress; Rats, Sprague-Dawley; Stroke

2021